PhaseII Study of Neoadjuvant and adjuvant Chemotherapy with Pemetrexed/Carboplatin/Bevacizumab in patients with non-squamouns non Small-cell lung cancer - PhaseII Study of Neoadjuvant and adjuvant Chemotherapy with Pemetrexed/Carboplatin/Bevacizumab in patients with non-squamouns non Small-cell lung cancer

Kansai Medical University Hirakata Hospital0 个研究点目标入组 35 人开始时间: 2012年10月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•>preoperative therapy (1) severe comorbit disease (2) history of hemoptysis, coagulation disorder and thrombosis or receive oral/i.v. hemostatic drug (3) With a clinical bleeding tendency (4) tumor cavitation and invasion to the major vessel (5) Patients of Untreated fracture (Such as compression fractures due to osteoporosis are excluded) or High degree of wound (7)Patients of the merger of infections requiring intravenous administration of anti-viral agents or anti-fungal agents,antibiotics (8) Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) (9) Patients with uncontrollable gastrointestinal ulceration (10) Patients with current or previous (within one year) history of gastrointestinal perforation (11) Patients with Symptomatic congestive heart failure,Unstable angina,Arrhythmia with treatment. Patients With a history of myocardial infarction within one year prior to registration. (12)In patients with persistent diarrhea. (There is a watery stool more than three times a day at the time of registration) (13) Patients with previous histories of drug allergy (14)history of drug induced interstitial pneumonia (15)regnant or lactating women or those who declined contraception (16)those judged to be not suitable by the attending physician >postoperative therapy (1) It is found that you have been registered in violation of the selection criteria or exclusion criteria (2) Apparent worsening of the disease due to cancer was observed

发起方

Kansai Medical University Hirakata Hospital